Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro

Abstract

The BM-MSCs exhibit extensive anti-proliferative properties against lymphocytes under different conditions. This property might offer a form of immunomodulatory cellular therapy for AD patients if further confirmed in animal models.

Multipotent mesenchymal stromal cells for autoimmune diseases: teaching new dogs old tricks

“…Although these encouraging results support an effect of infused MSCs in the prevention of GVHD, an increased occurrence of leukemia relapses has been reported because of the inhibition of leukemic cell-specific T-cell responses. 85 MSCs from human autoimmune disease Autologous BM-derived MSCs have been shown to be potently antiproliferative to stimulated T-cells from normal participants and autoimmune (RA, SSc, Sjoegren's, SLE) patients, 86 and in SSc patients these MSCs were normal with respect to proliferation, clonogenicity and differentiation to bone and fat. 87 However, one group has shown defective differentiation into endothelial precursors in BM-derived MSCs from SSc patients, 88 which should be considered when choosing autologous or allogeneic MSC sources for SSc treatment.…”

The Murine Pbx1-d Lupus Susceptibility Allele Accelerates Mesenchymal Stem Cell Differentiation and Impairs Their Immunosuppressive Function

“…Additionally, MSCs from lupus have defective functions, with an impaired differentiation into osteoblasts (18), enhanced senescence and apoptosis, as well as impaired self-renewal (19,20), providing potential mechanisms for the observed failure of autologous MSC therapies. One study, however, reported that MSCs from autoimmune patients presented immunosuppressive properties similar to those of healthy controls (21). Mixed results have also been obtained with mouse models of lupus (17).…”

Mesenchymal Stem Cells: Possibilities of New Treatment Options

“…Chang et al ( 2006 ) declared that the suppression of stimulated lymphocyte reactivation by placenta-derived MSCs was due to decreased cell proliferation and increased numbers of regulatory T cells but not by cell death. Finally, it has been indicated that the BM-MSCs, obtained from both healthy and autoimmune-disease persons, suppressed proliferation of the stimulated autologous and allogeneic peripheral blood mononuclear cells as much as 90% (Bocelli-Tyndall et al 2007 ) .…”